FDA Approves First Immunotherapy Add-On for Stage III Colon Cancer With a Common Tumor Marker, Cutting Recurrence Risk in Half

On October 8, 2026, the FDA approved atezolizumab (Tecentriq), along with its new subcutaneous formulation Tecentriq Hybreza, as an add-on to standard chemotherapy after surgery for patients with stage III colon cancer whose tumors are mismatch repair-deficient (dMMR) — a genetic signature found in roughly 15% of colon cancers. The decision, built on a National Cancer Institute-funded, academic-led trial, marks the first time immunotherapy has been approved specifically for early-stage, surgically resected colon cancer in this biomarker-defined group, and it cut the risk of recurrence or death in half compared with chemotherapy alone. This article walks through what was approved, the data behind it, who it helps, and where the open questions remain.

A New Option After Surgery, Not Just for Advanced Disease

Immune checkpoint inhibitors like atezolizumab have been used for years in metastatic, dMMR/MSI-high colorectal cancer. What's new here is the setting: this approval moves the drug into the adjuvant space — given after a tumor has already been surgically removed, specifically to prevent it from coming back. That distinction matters clinically. Stage III colon cancer means the disease has spread to nearby lymph nodes but not to distant organs, and the standard approach after surgery has long been several months of chemotherapy (commonly FOLFOX, a fluoropyrimidine-oxaliplatin combination) aimed at mopping up microscopic residual disease. Adding an immunotherapy to that regimen, rather than reserving it for relapsed or metastatic disease, is a meaningfully earlier intervention point.

The approval covers two formulations: standard intravenous atezolizumab, cleared for adults and children as young as 2, and Tecentriq Hybreza, a subcutaneous injection (combined with hyaluronidase) cleared for patients 12 and older weighing at least 40 kg — a formulation intended to cut treatment-chair time from roughly 30-60 minutes for an IV infusion to about 7 minutes for an injection. Both are approved in combination with a fluoropyrimidine and oxaliplatin (the mFOLFOX6 backbone) specifically for stage III dMMR colon cancer after complete surgical removal of the primary tumor, with no residual nodal involvement or metastatic spread.

The Trial Behind the Approval

The approval rests on the Phase III ATOMIC trial (also known as A021502, NCT02912559), a randomized, open-label study led by the Alliance for Clinical Trials in Oncology — a National Cancer Institute-supported cooperative research group — in partnership with Genentech (through a formal cooperative research agreement with NCI) and the German oncology group AIO. That structure is itself notable: this is a case of a publicly funded academic trial network, not a drugmaker alone, designing and running the pivotal study that led to a new indication, with NCI/NIH underwriting much of the research infrastructure.

ATOMIC enrolled 712 participants (711 adults and one pediatric patient) between 2017 and 2023 across the United States and Germany, all with surgically resected stage III dMMR colon cancer. More than a quarter of participants were under age 50, and the trial specifically included patients with Lynch syndrome, an inherited condition that predisposes people to dMMR cancers — a population that stands to benefit disproportionately given their earlier age of onset and lifetime recurrence risk. Patients were randomized 1:1 to receive mFOLFOX6 chemotherapy alone for 12 cycles, or the same chemotherapy plus atezolizumab for 12 cycles followed by six additional months of atezolizumab alone.

The results, which were first presented at ASCO in 2025 and have now translated into regulatory approval, were striking by adjuvant-oncology standards. At three years, 86.3% of patients who received atezolizumab plus chemotherapy were disease-free, compared with 76.2% of those who received chemotherapy alone — a difference reflected in a hazard ratio of 0.50 (95% CI, 0.35–0.73; p = 0.0001), meaning the combination cut the relative risk of cancer recurrence or death roughly in half. Notably, median disease-free survival was not yet reached in either arm, underscoring how durable the benefit appears for many patients. The FDA granted the application priority review and evaluated it alongside regulators in Australia, Canada, Israel, and Switzerland under the Project Orbis international collaboration, several of which have reviews still in progress.

What It Means for Patients — and the Real Caveats

For the subset of colon cancer patients whose tumors carry the dMMR signature, this is genuinely good news: a one-year course of additional treatment, now available as either an infusion or a quick subcutaneous injection, associated with a substantial reduction in recurrence risk at a point in care — right after surgery — when preventing relapse has an outsized effect on long-term survival. As ATOMIC study chair Dr. Frank Sinicrope put it, the approval "represents a major advance for patients with a subset of stage 3 colon cancer," adding that preventing recurrence in younger patients "can translate into decades of life gained." Alliance Group Chair Dr. Evanthia Galanis noted the trial demonstrates the value of "introducing immunotherapy earlier in the course of cancer treatment."

That said, several caveats deserve equal weight. First, this benefit applies only to the roughly 15% of colon cancers that are dMMR/MSI-high — most colon cancer patients will not qualify, and testing tumors for mismatch-repair status (now effectively a prerequisite for this decision) needs to be routine for patients to be identified. Second, while disease-free survival gains of this magnitude are rare and encouraging, overall survival data — the ultimate measure of whether lives are extended, not just recurrence delayed — is still maturing; DFS is a validated surrogate in this setting but not identical to a survival benefit. Third, the trial was open-label (not blinded), a design limitation common in surgical/adjuvant oncology trials but one that can introduce reporting bias in softer endpoints. Finally, atezolizumab carries the class-wide risks of checkpoint inhibitors: immune-mediated adverse reactions affecting the lungs, liver, colon, endocrine glands, skin, and other organs, infusion-related reactions, complications in patients who later need an allogeneic stem cell transplant, and embryo-fetal toxicity — risks that are generally manageable but require monitoring and are not trivial over a 12-month treatment course.

Bottom Line

The FDA's approval of atezolizumab for stage III dMMR colon cancer gives a biomarker-defined group of patients — including many younger adults and those with Lynch syndrome — a new, evidence-backed option that nearly halved recurrence risk in a rigorously run, NCI-funded trial, with a convenient subcutaneous option now available alongside the standard infusion. It's a real and well-earned milestone in moving immunotherapy earlier into curative-intent cancer care. But it's not a cure-all: it helps a specific subset of colon cancer patients, overall survival data is still accruing, and the therapy carries the genuine immune-related risks that come with any checkpoint inhibitor. Patients with stage III colon cancer should ask whether their tumor has been tested for mismatch-repair status and discuss with their oncology team whether this regimen fits their specific case.